Dr. François Emond completed his medical degree at Laval University in 1997 and his residency in adult neurology in 2002. After a clinical fellowship in multiple sclerosis at The Ottawa Hospital under the direction of Dr. Mark S. Freedman, he joined the neurology department of the CHU of Quebec-Hôpital de l’Enfant-Jésus. Since 2012, he has been director of the multiple sclerosis clinic at the CHU of Quebec and IRDPQ (CIUSSS Capitale-Nationale – François-Charron Centre). In addition to following several hundred patients with multiple sclerosis, he regularly participates in teaching students, externs and residents of the RUIS-Laval network.
Since 2003, Dr. Emond has been involved, as primary local investigator or co-investigator, in multiple clinical trials on the long-term treatment of multiple sclerosis.
Département des sciences neurologiques
Québec, Québec
Canada G1J 1Z4
Latest news
Data not available
- Blanchet, ManonEmployeeHôpital de l'Enfant-Jésus+1 418-649-0252, extension 63530manon.blanchet@crchudequebec.ulaval.ca
1401 18e Rue
Recherche neuromusculaire
P-0140
Québec, QC
Canada G1J 1Z4 - Simard, AlexandraEmployeeHôpital de l'Enfant-Jésus+1 418-649-0252, extension 63559Alexandra.Simard@crchudequebec.ulaval.ca
1401, 18e Rue
Recherche neuromusculaire
P-0145
Québec, Québec
Canada G1J 1Z4
Health Canada Drug Approval Process: A Barrier to Personalized Care in Multiple Sclerosis
Journal ArticleCan J Neurol Sci, 2024.
Case Report: Acute Necrotizing Encephalopathy Following COVID-19 Vaccine
Journal ArticleFront Neurol, 13 , 2022.
Cortical morphology predicts placebo response in multiple sclerosis
Journal ArticleSci Rep, 12 (1), 2022.
Sequencing of high-efficacy disease-modifying therapies in multiple sclerosis: perspectives and approaches
Journal ArticleNeural Regen Res, 13 (11), 2018.
Safety and efficacy of venoplasty in MS: A randomized, double-blind, sham-controlled phase II trial
Journal ArticleNeurology, 91 (18), 2018.
Sequencing of disease-modifying therapies for relapsing-remitting multiple sclerosis: a theoretical approach to optimizing treatment
Journal ArticleCurr Med Res Opin, 34 (8), 2018.
Pulvinar sign in a case of anti-HU paraneoplastic encephalitis
Journal ArticleNeuroradiol J, 29 (6), 2016.
Treatment optimization in MS: Canadian MS Working Group updated recommendations
Journal ArticleCan J Neurol Sci, 40 (3), 2013.
LRRK2 is not a significant cause of Parkinson's disease in French-Canadians
Journal ArticleCan J Neurol Sci, 34 (3), 2007.